MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A.

Yuan, Daozhang; Zheng, Shunsheng; Wang, Liyan; Li, Jing; Yang, Jianan; Wang, Bin; Chen, Xiong; Zhang, Xiaobo.

Affiliation

Yuan D; Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China.
Zheng S; Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China.
Wang L; Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China.
Li J; Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China.
Yang J; Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China.
Wang B; Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China.
Chen X; Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Zhang X; Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha, People's Republic of China.

Oncotarget ; 8(40): 67663-67669, 2017 Sep 15.

Article in En | MEDLINE | ID: mdl-28978061